Certara (CERT) has just wrapped up FY 2025 with fourth quarter revenue of US$103.6 million and a basic EPS loss of US$0.04, as net income excluding extra items came in at a loss of US$5.9 million. The company has seen quarterly revenue move from US$100.4 million in Q4 2024 to US$106.0 million in Q1 2025, US$104.6 million in Q3 2025 and US$103.6 million in Q4 2025, while basic EPS has swung between a profit of US$0.04 in Q4 2024 and Q1 2025 and losses of up to US$0.04 in Q4 2025. Investors are likely to focus on how efficiently Certara is converting its steady top line into improved margins over time.

See our full analysis for Certara.

With the headline numbers on the table, the next step is to see how this earnings print lines up with the prevailing narratives around Certara's growth potential, profitability path and risk profile.

TTM results show small annual loss

• Over the last twelve months, Certara generated total revenue of US$418.8 million and a net loss excluding extra items of US$1.6 million, which is a much smaller loss than the US$12.1 million TTM loss reported a year earlier.
• What stands out for the bullish view is that this shrinking loss sits alongside forecasts for earnings to grow at 66.6% per year, so:
  • The five year annual reduction in losses of 21.8% lines up with the idea that profitability could improve if that trend continues, even though the latest year is still slightly in the red.
  • At the same time, revenue is only forecast to grow at 5.9% per year, which is slower than the cited 10.4% for the US market. Bulls are therefore leaning heavily on margin improvement rather than rapid sales growth.

Bulls argue this mix of modest revenue growth and faster earnings improvement could make the current loss a stepping stone rather than a setback, and the full bull case is laid out in more depth in the 🐂 Certara Bull Case

Quarterly EPS swings around breakeven

• Across FY 2025, basic EPS moved from a profit of US$0.03 in Q1 to a small loss of US$0.01 in Q2, back to a profit of roughly US$0.01 in Q3 and then to a loss of about US$0.04 in Q4, showing results flipping between profit and loss even as quarterly revenue held in a tight US$103 million to US$106 million range.
• Skeptics highlight these swings as a risk for the bearish narrative, because:
  • The bearish case assumes revenue can still grow at 7.4% per year with profit margins rising from 2.6% to 4.1%, yet the recent pattern of small profits followed by losses suggests that near term earnings are sensitive to relatively small changes in costs or mix.
  • With Certara still unprofitable on a TTM basis, bears argue that relying on margin expansion from a low base leaves less room for error if pharma customers delay projects or if services bookings remain soft.

Skeptical investors who want to see how this cautious view is built up from the numbers can walk through the full bear case in the 🐻 Certara Bear Case

Valuation gap versus DCF and targets

• Certara trades at a P/S ratio of 2.6x, compared with 2.2x for the US Healthcare Services industry and 2.8x for its peer group, while a DCF fair value of about US$21.00 and an allowed analyst price target of US$11.86 both sit above the current share price of US$6.80 in the data.
• Consensus narrative comments on this spread by pointing out that:
  • The DCF fair value being far above the current price implies a large valuation gap in that model, even though revenue growth is only forecast at 5.9% per year and the company is still loss making on a TTM basis.
  • At the same time, the allowed analyst price target of US$11.86 is much closer to the market price than the DCF figure. This shows how different valuation methods and assumptions can lead to very different views on what Certara might be worth.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Certara on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If the mix of bull and bear arguments here feels split, do not wait on others to decide for you. Check the data yourself and see how 3 key rewards stack up against your own expectations.

See What Else Is Out There

Certara's small but persistent TTM loss, breakeven level EPS swings and reliance on margin improvement rather than strong revenue growth may concern some investors.

If that mix of thin profitability and choppy earnings feels uncomfortable, you might want to balance your watchlist by checking out 80 resilient stocks with low risk scores that aim to keep overall portfolio risk in check.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.